Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABM-1310 in BRAF V600-Mutant Primary Malignant Brain Tumors
NCT05892653Phase 1Terminated
- Sponsor
- ABM Therapeutics
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abm-1310 in primary malignant brain tumor, sponsored by ABM Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 8 more. Started Jun 2023; status: terminated.
02
Drugs
abm-1310
03
Conditions
primary malignant brain tumor
Beyond the preview
Go deeper on NCT05892653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05892653.